Nelson Capital Management LLC Takes $2.53 Million Position in Boston Scientific Corporation $BSX

Nelson Capital Management LLC bought a new stake in Boston Scientific Corporation (NYSE:BSX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,924 shares of the medical equipment provider’s stock, valued at approximately $2,531,000.

A number of other institutional investors have also recently bought and sold shares of the business. Certuity LLC lifted its holdings in shares of Boston Scientific by 32.3% during the 3rd quarter. Certuity LLC now owns 5,383 shares of the medical equipment provider’s stock worth $525,000 after acquiring an additional 1,314 shares during the period. Johnson Financial Group Inc. increased its stake in Boston Scientific by 196.4% in the third quarter. Johnson Financial Group Inc. now owns 735 shares of the medical equipment provider’s stock valued at $72,000 after acquiring an additional 487 shares during the period. Arrowstreet Capital Limited Partnership raised its position in Boston Scientific by 28.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 8,367,398 shares of the medical equipment provider’s stock worth $816,909,000 after purchasing an additional 1,837,480 shares in the last quarter. Invesco Ltd. lifted its stake in Boston Scientific by 0.7% during the third quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock worth $1,656,131,000 after purchasing an additional 111,826 shares during the period. Finally, Seven Mile Advisory boosted its holdings in Boston Scientific by 26.4% during the third quarter. Seven Mile Advisory now owns 3,802 shares of the medical equipment provider’s stock valued at $371,000 after purchasing an additional 795 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

BSX traded down $0.06 during trading on Friday, hitting $68.49. The company’s stock had a trading volume of 478,383 shares, compared to its average volume of 15,618,364. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $101.63 billion, a price-to-earnings ratio of 35.43, a price-to-earnings-growth ratio of 0.97 and a beta of 0.69. The firm’s 50 day moving average price is $82.98 and its two-hundred day moving average price is $93.64. Boston Scientific Corporation has a 12 month low of $67.56 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the prior year, the business earned $0.70 earnings per share. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BSX shares. TD Cowen cut their target price on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. National Bank Financial set a $115.00 price target on Boston Scientific in a research report on Monday, February 2nd. Robert W. Baird dropped their price objective on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Canaccord Genuity Group cut their price objective on Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Finally, Royal Bank Of Canada reduced their target price on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $108.00.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Citigroup cut its price target for Boston Scientific from $102 to $94 but kept a “buy” rating, continuing to model meaningful upside versus the current share level — this leaves institutional endorsement in place even after the trim. Read More. Read More.
• Neutral Sentiment: Market‑coverage writeup explaining today’s larger-than-market decline points to the combination of the analyst update and mounting legal notices as the proximate cause of the volatility. Read More.
• Negative Sentiment: A wave of securities‑class‑action alerts and filings allege misstatements (notably about U.S. electrophysiology volumes) for the period July 23, 2025–Feb 3, 2026; multiple plaintiff firms are soliciting lead‑plaintiff motions with a May 4, 2026 deadline. The proliferation of filings and publicity increases litigation risk, potential legal costs, and management distraction — a material near‑term overhang for the stock. Representative notices: Read More., Read More., Read More., and Read More..

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.